SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 160 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,179,902 | +150.5% | 150,131 | +261.0% | 0.00% | – |
| Q2 2023 | $870,374 | -35.0% | 41,585 | -34.4% | 0.00% | -100.0% |
| Q1 2023 | $1,338,733 | +181.9% | 63,387 | +239.7% | 0.00% | – |
| Q4 2022 | $474,898 | -0.4% | 18,660 | -14.3% | 0.00% | – |
| Q4 2021 | $477,000 | +12.2% | 21,778 | +14.4% | 0.00% | – |
| Q1 2021 | $425,000 | -63.8% | 19,033 | -64.0% | 0.00% | -100.0% |
| Q4 2020 | $1,175,000 | +7.4% | 52,846 | -28.5% | 0.00% | – |
| Q2 2020 | $1,094,000 | – | 73,875 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |